SCLC (Small Cell Lung Cancer) Epidemiology Forecast

$ 9.590,00

SCLC (Small Cell Lung Cancer) Epidemiology Forecast

Lung cancer is the leading cause of cancer deaths in both men and women. The causal connection between cigarettes and lung cancer is now established, with a specific identification of carcinogens in tobacco smoke. It is estimated that cigarette smoking causes 85% to 90% of cases of lung cancer

  • Countries concerned :

Add to my wishlist

In the G7 mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK), Hoffmann-Krueger epidemiologists expect the incident cases of SCLC (Small Cell Lung Cancer) to increase from 72 451 cases in 2012 to 83 405 cases in 2022.


Scope: G7 Mature markets (the USA, Japan, France, Germany, Italy, Spain, the UK)

10-year patient population forecast + 5 years of historical data


Key Users:  Oncology Market Research - New Product Planning - Business Development & Licensing

Oncology Market Access – Oncology Marketing leaders


Insight: Insight into the SCLC (Small Cell Lung Cancer) cancer strategy and business development activities

Transparent forecasts methodology and assumptions

Concise and comparable analysis


Key epidemiology assumptions are included to give accurate sizing of patient population, epidemiology forecast, key drivers of patient shares.


The oncology drug market is one of the fastest-growing markets in the pharmaceutical industry. The treatment of cancer has shifted away from mass market blockbuster drugs toward a more focused attack on the disease with targeted therapies.


Reasons To Buy


Hoffmann-Krueger ECF (Epidemiology Cancer Forecast) rich data set and easy-to-use tool allow you to focus on cancer subpopulation segment of interest. Hoffmann-Krueger  ECF (Epidemiology Cancer Forecast) giving the opportunity to use epidemiological projections of key oncology patient population.

  • Country : Japan | Germany | United States | Spain | Italy | France | United Kingdom
  • Cancer Type : Lung SCL
  • File : xls